Heterogeneity of gestational diabetes - Do we take MODY into consideration as much as we should?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10385476" target="_blank" >RIV/00064203:_____/19:10385476 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/19:43917436 RIV/00216208:11130/19:10385476

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CX7tGJMLny" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CX7tGJMLny</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.diabres.2018.11.009" target="_blank" >10.1016/j.diabres.2018.11.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Heterogeneity of gestational diabetes - Do we take MODY into consideration as much as we should?

Popis výsledku v původním jazyce

We read with interest the article by Ryan DK et al. focused on early screening and treatment of gestational diabetes (GDM) in &quot;high-risk women&quot; that has been published recently in the journal [1]. We do not have any critical remarks directly to the study itself but in connection with this topic we consider it important to highlight an area of Maturity Onset Diabetes of the Young (MODY) which is closely connected and usually overlooked. MODY comprises the group of 14 (yet recognized) specific types of diabetes with autosomal dominant inheritance, with the mutations in gene encoding glucokinase enzyme (GCK) and genes encoding transcription factors - hepatocyte nuclear factor 1α (HNF1A) and 4α (HNF4A) being the most prevalent [2]. The prevalence of GCK-MODY among pregnant women diagnosed with GDM may reach 5% [3]. In HNF1A-MODY or HNF4A-MODY it is lower - up to 1% [3]. The correct diagnosis of MODY is, however, important, as management of GCK-MODY and HNF4A-MODY during and after pregnancy is different from other forms of GDM (e.g. in prevention of developing foetal macrosomia in GCK-MODY [4] and HNF4A-MODY, in preventing neonatal hyperinsulinemic hypoglycemia in the offspring of parents with HNF4A-MODY[5], and in the subsequent management of diabetes therapy specific to each MODY type [2]). HNF1A-MODY is not associated with the above mentioned risks, as hyperglycaemia caused by HNF1A gene mutation can be managed with insulin or sulfonylurea derivatives and thus results in normal size-infants [2]. Nevertheless, poorly controlled diabetes (of any type) increases the risk of perinatal complications concerning both, the mother and the baby. GCK-MODY and also HNF1A-MODY or HNF4A-MODY can be distinguished from GDM by conducting a detailed analysis of their usual features (a mild fasting hyperglycaemia, a small increment in the 120th minute during an oral glucose tolerance test (oGTT), a near normal HbA1c and BMI, a positive family history [2], and current pregnancy-specific screening criteria (combination of pre-pregnancy BMI &lt; 25 kg/m2 and fasting glucose GREATER-THAN OR EQUAL TO 5.5 mmol/L during pregnancy [4])). However, it should be mentioned that the validity of BMI, HbA1c, oGTT findings and family history as discriminatory markers has been questioned [3]. Later, during regular check-ups post partum or in subsequent pregnancy, other criteria, such as foetal macrosomia and insulin requirement only during pregnancy with subsequent control on diet [4], may additionally lead to suspicion of GCK-MODY. Thus, in our opinion, MODY should be considered in differential diagnosis of GDM more routinely.

Název v anglickém jazyce

Heterogeneity of gestational diabetes - Do we take MODY into consideration as much as we should?

Popis výsledku anglicky

We read with interest the article by Ryan DK et al. focused on early screening and treatment of gestational diabetes (GDM) in &quot;high-risk women&quot; that has been published recently in the journal [1]. We do not have any critical remarks directly to the study itself but in connection with this topic we consider it important to highlight an area of Maturity Onset Diabetes of the Young (MODY) which is closely connected and usually overlooked. MODY comprises the group of 14 (yet recognized) specific types of diabetes with autosomal dominant inheritance, with the mutations in gene encoding glucokinase enzyme (GCK) and genes encoding transcription factors - hepatocyte nuclear factor 1α (HNF1A) and 4α (HNF4A) being the most prevalent [2]. The prevalence of GCK-MODY among pregnant women diagnosed with GDM may reach 5% [3]. In HNF1A-MODY or HNF4A-MODY it is lower - up to 1% [3]. The correct diagnosis of MODY is, however, important, as management of GCK-MODY and HNF4A-MODY during and after pregnancy is different from other forms of GDM (e.g. in prevention of developing foetal macrosomia in GCK-MODY [4] and HNF4A-MODY, in preventing neonatal hyperinsulinemic hypoglycemia in the offspring of parents with HNF4A-MODY[5], and in the subsequent management of diabetes therapy specific to each MODY type [2]). HNF1A-MODY is not associated with the above mentioned risks, as hyperglycaemia caused by HNF1A gene mutation can be managed with insulin or sulfonylurea derivatives and thus results in normal size-infants [2]. Nevertheless, poorly controlled diabetes (of any type) increases the risk of perinatal complications concerning both, the mother and the baby. GCK-MODY and also HNF1A-MODY or HNF4A-MODY can be distinguished from GDM by conducting a detailed analysis of their usual features (a mild fasting hyperglycaemia, a small increment in the 120th minute during an oral glucose tolerance test (oGTT), a near normal HbA1c and BMI, a positive family history [2], and current pregnancy-specific screening criteria (combination of pre-pregnancy BMI &lt; 25 kg/m2 and fasting glucose GREATER-THAN OR EQUAL TO 5.5 mmol/L during pregnancy [4])). However, it should be mentioned that the validity of BMI, HbA1c, oGTT findings and family history as discriminatory markers has been questioned [3]. Later, during regular check-ups post partum or in subsequent pregnancy, other criteria, such as foetal macrosomia and insulin requirement only during pregnancy with subsequent control on diet [4], may additionally lead to suspicion of GCK-MODY. Thus, in our opinion, MODY should be considered in differential diagnosis of GDM more routinely.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes Research and Clinical Practice

ISSN

0168-8227

e-ISSN

—

Svazek periodika

148

Číslo periodika v rámci svazku

February

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

2

Strana od-do

268-269

Kód UT WoS článku

000458859200030

EID výsledku v databázi Scopus

2-s2.0-85061643308